FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name ar	2. Issuer Name and Ticker or Trading Symbol HELIUS MEDICAL TECHNOLOGIES, INC. [ HSDT ]									5. Relationship of Report (Check all applicable)  X Director  V Officer (give title			X 10%		Issuer Owner r (specify					
(Last) (First) (Middle) C/O HELIUS MEDICAL TECHNOLOGIES, INC.					3. Date of Earliest Transaction (Month/Day/Year) 12/14/2023									X	below	<i>(</i> )	below resident and CEO			
642 NEWTOWN YARDLEY ROAD, SUITE 100						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) NEWTOWN PA 18940														X Form filed by One Reporting Person  Form filed by More than One Reporting  Person						
(City) (State) (Zip)				Rule 10b5-1(c) Transaction Indication																
	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																			
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Date					te		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)					nd Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price	_	Reported Transact (Instr. 3	tion(s)			(Instr. 4)	
Common Stock 12/					12/14/2023				P		2,827	A	\$8.09	.095 16,512		I		See footnote <sup>(1)</sup>		
Common Stock				12/14/2023					P		570	A	\$8.09	8.095 3,4		102	2 I		See footnote <sup>(2)</sup>	
Common Stock 12/1				12/14/20	12/14/2023				P		1,603	A	\$8.09	95	12,879		I		See footnote <sup>(3)</sup>	
Common Stock															5	99		Ι	See footnote <sup>(4)</sup>	
Common Stock													3		30	D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution   urity or Exercise (Month/Day/Year) if any		ution Date,	on Date, Transa				6. Date Exel Expiration I (Month/Day)		Date	7. Title and Amount of Securities Underlying Derivative Security (Instr 3 and 4)		nt		9. Numbe derivative Securitie Beneficia Owned Followine Reported Transacti (Instr. 4)	e s ally g	10. Ownersh Form: Direct (D) or Indirec (I) (Instr.	Beneficial Ownership tt (Instr. 4)		
					Code	v	(A) (I	D)	Date Exerc	isable	Expiration Date		Number of Shares							

## Explanation of Responses:

- 1. The shares are held by Maple Leaf Partners, L.P. ("MLP"). The reporting person is the managing member of Maple Leaf Capital I, LLC ("Maple Leaf Capital"), the general partner of MLP and as such may be deemed to beneficially own the securities owned by MLP. The reporting person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported shares for purposes of Section 16 or for any other purposes.
- 2. The shares are held by Maple Leaf Partners I, L.P. ("MLP I"). The reporting person is the managing member of Maple Leaf Capital, the general partner of MLP I and as such may be deemed to beneficially own the securities owned by MLP I. The reporting person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported shares for purposes of Section 16 or for any other purposes.
- 3. The shares are held by Maple Leaf Discovery I, L.P. ("MLD I"). The reporting person is the managing member of Maple Leaf Capital, the general partner of MLD I and as such may be deemed to beneficially own the securities owned by MLD I. The reporting person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported shares for purposes of Section 16 or for any other purposes.
- 4. The shares are held by Maple Leaf Offshore Ltd. ("MLO"). The reporting person is the president of the managing member of Andreeff Equity Advisors, L.L.C., the investment manager of MLO and as such may be deemed to beneficially own the securities owned by MLO. The reporting person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported shares for purposes of Section 16 or for any other purposes.

/s/ Dane Andreeff

12/15/2023

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.